Pharmaceuticals

BioScience Today article: Shanks v Unilever – An opening of the claim floodgates?

Solicitor Varuni Paranavitane writes for BioScience Today on the subject of Shanks v Unilever – An opening of the claim floodgates? This article was originally written for BioScience today, you can find Varuni’s article below, or read the full magazine here.   BACKGROUND In 2006 Professor Shanks claimed compensation under s40 of the Patents Act on… Read more »

News in brief from the pharma and medical devices sectors – Summer 2019 trade mark decisions from the UK and EU

Senior Associate Suzanne Power reports on the Summer 2019 trade mark decisions from the UK and EU in the Pharma and Med Dev sectors. 1. Slogans remain difficult to register as EU trade marks – Case T-555/18 of 3 April 2019, Medrobotics Corp. v EUIPO This decision from the EU’s General Court (“GC”) highlights the… Read more »

AA Thornton are ranked in the Legal 500 2020

AA Thornton is ranked as a top tier firm The Legal 500 2020 edition has now been published and we are absolutely delighted to be recommended as a top-tier firm for our trade marks practice, which was described as “strong”, “dedicated” and an “excellent team of knowledgeable and genuinely good people”. We also remain highly recommended for our patents… Read more »

Biosimilars and patents

The majority of the world’s biggest selling medicines can be classified as “biologics” or “biopharmaceuticals”. Such medicines contain one or more biologically active product produced from (or containing components of) living organisms as the active ingredients.   Biosimilars are biological products which are highly similar in structure, biological activity, efficacy, safety and immunogenicity profile to… Read more »

Patent protection of medical devices

Patent protection of medical devices – time for a rethink? This article was first published by Bio Science Today in March 2019 Introduction The duration of patent protection for medical devices is up to twenty years, as for any other type of device. Pharmaceuticals, on the other hand, may be entitled to an extended duration… Read more »

Legal update: Eli Lilly v Genentech – Warner-Lambert

Eli Lilly v Genentech – Warner-Lambert Supreme Court Plausibility Test Applied Following the highly anticipated Supreme Court decision in Warner-Lambert v Generics in relation to plausibility at the end of last year, the UK High Court has recently applied the new plausibility test for the first time in Eli Lilly v Genentech Inc.1 Eli Lilly… Read more »

Julie Barrett-Major speaks at Queen Mary University

Reporting on the Queen Mary University’s Life Sciences, Cosmetics and Intellectual Property seminars for CNIPA Consulting Patent Attorney Julie Barrett-Major recently gave two 3-hour seminars at the Queen Mary University of London (QMUL) earlier this month on Life Sciences, Cosmetics and Intellectual Property. The two seminars formed part of the QMUL’s programme of education and training… Read more »

East Anglia Business Magazine: The Importance of Intellectual Property

The Importance of Intellectual Property Associate Attorney, Christopher Burnett, recently wrote an article ‘The Importance of Intellectual Property’ for East Anglia in Business Magazine, and the full magazine can be read  here.. Chris’s article identifies different IP rights, what they protect and how they are obtained in order to then commercialise them. Below is Chris’s… Read more »

An update on Supplementary Protection Certificates in Europe

European Commission proposes changes to Supplementary Protection Certificates Supplementary Protection Certificates (SPCs) are an intellectual property right that serve as an extension to a patent right (for up to five years) specific to pharmaceutical and plant products that must undergo extensive testing and clinical trials before being authorised by marketing authorities in Europe. Earlier in 2018,… Read more »

Categories

Archives